{"title_page": "Axelopran", "text_new": "{{Refimprove|date=June 2015}}\n{{Drugbox\n| Verifiedfields = \n| Watchedfields = \n| verifiedrevid = \n| IUPAC_name = <nowiki>3-[(1R,5S)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide</nowiki>\n| image = Axelopran_structure.png\n| width = 240\n\n<!--Clinical data-->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = \n| CAS_number = 949904-48-7\n| CAS_supplemental = <br />{{CAS|949904-50-1}} ([[sulfate]])\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 85U7ROB149\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = 67156338\n| DrugBank_Ref = \n| DrugBank = \n| ChemSpiderID_Ref = \n| ChemSpiderID = 31444004\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG = D10740\n\n<!--Chemical data-->\n| C=26 | H=39 | N=3 | O=4\n| molecular_weight = 457.60556 g/mol\n| smiles = C1CCC(CC1)CN(CCN2C3CCC2CC(C3)C4=CC=CC(=C4)C(=O)N)C(=O)C(CO)O\n| StdInChI =1S/C26H39N3O4/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32)/t21-,22+,23-,24-/m0/s1\n| StdInChIKey = ATLYLVPZNWDJBW-KIHHCIJBSA-N\n| synonyms = \n}}\n'''Axelopran''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''TD-1211''') is a [[Pharmaceutical drug|drug]] which is under development by [[Theravance Biopharma]] for the treatment of [[opioid]]-induced [[constipation]]. It acts as a [[peripherally acting \u03bc-opioid receptor antagonist]] and also acts on [[\u03ba-opioid receptor|\u03ba-]], and [[\u03b4-opioid receptor]]s, with similar [[affinity (pharmacology)|affinity]] for the \u03bc- and \u03ba-opioid receptors and about an order of magnitude lower affinity for the \u03b4-opioid receptor. Axelopran has potent \u03bc-opioid receptor antagonist activity on the [[gastrointestinal tract]] ''[[in vivo]]'', and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following [[subcutaneous injection|subcutaneous]] or [[Mouth|oral]] administration.<ref name=\"Axelopran FDA Information\">[https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM400210.pdf], Axelopran (td-1211) briefing document anesthetic and analgesic drug products advisory committee June 11 and 12, 2014.</ref>\n\n==See also==\n* [[Bevenopran]]\n* [[Eluxadoline]]\n* [[Methylnaltrexone]]\n* [[Naldemedine]]\n\n==References==\n{{Reflist}}\n\n\n{{Laxatives}}\n{{Opioidergics}}\n\n[[Category:Drugs acting on the gastrointestinal system and metabolism]]\n[[Category:Kappa antagonists]]\n[[Category:Laxatives]]\n[[Category:Opioid antagonists]]\n\n\n{{gastrointestinal-drug-stub}}\n", "text_old": "{{Refimprove|date=June 2015}}\n{{Drugbox\n| Verifiedfields = \n| Watchedfields = \n| verifiedrevid = \n| IUPAC_name = <nowiki>3-[(1R,5S)-8-[2-[cyclohexylmethyl-[(2S)-2,3-dihydroxypropanoyl]amino]ethyl]-8-azabicyclo[3.2.1]octan-3-yl]benzamide</nowiki>\n| image = Axelopran_structure.png\n| width = 240\n\n<!--Clinical data-->\n| tradename = \n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B            / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion =\n\n<!--Identifiers-->\n| CAS_number_Ref = \n| CAS_number = 949904-48-7\n| CAS_supplemental = <br />{{CAS|949904-50-1}} ([[sulfate]])\n| ATC_prefix = none\n| ATC_suffix = \n| PubChem = 67156338\n| DrugBank_Ref = \n| DrugBank = \n| ChemSpiderID_Ref = \n| ChemSpiderID = 31444004\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG = D10740\n\n<!--Chemical data-->\n| C=26 | H=39 | N=3 | O=4\n| molecular_weight = 457.60556 g/mol\n| smiles = C1CCC(CC1)CN(CCN2C3CCC2CC(C3)C4=CC=CC(=C4)C(=O)N)C(=O)C(CO)O\n| StdInChI =1S/C26H39N3O4/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32)/t21-,22+,23-,24-/m0/s1\n| StdInChIKey = ATLYLVPZNWDJBW-KIHHCIJBSA-N\n| synonyms = \n}}\n'''Axelopran''' ([[International Nonproprietary Name|INN]], [[United States Adopted Name|USAN]]) (developmental code name '''TD-1211''') is a [[Pharmaceutical drug|drug]] which is under development by [[Theravance Biopharma]] for the treatment of [[opioid]]-induced [[constipation]]. It acts as a [[peripherally acting \u03bc-opioid receptor antagonist]] and also acts on [[\u03ba-opioid receptor|\u03ba-]], and [[\u03b4-opioid receptor]]s, with similar [[affinity (pharmacology)|affinity]] for the \u03bc- and \u03ba-opioid receptors and about an order of magnitude lower affinity for the \u03b4-opioid receptor. Axelopran has potent \u03bc-opioid receptor antagonist activity on the [[gastrointestinal tract]] ''[[in vivo]]'', and thus it produces a dose-dependent inhibition of opioid-induced delaying in gastric emptying in mice and rats following [[subcutaneous injection|subcutaneous]] or [[Mouth|oral]] administration.<ref name=\"Axelopran FDA Information\">[https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM400210.pdf], Axelopran (td-1211) briefing document anesthetic and analgesic drug products advisory committee June 11 and 12, 2014.</ref>\n\n==See also==\n* [[Bevenopran]]\n* [[Eluxadoline]]\n* [[Methylnaltrexone]]\n* [[Naldemedine]]\n\n==References==\n{{Reflist}}\n\n\n{{Laxatives}}\n{{Opioidergics}}\n\n[[Category:Drugs acting on the gastrointestinal system and metabolism]]\n[[Category:Kappa antagonists]]\n[[Category:Laxatives]]\n[[Category:Opioid antagonists]]\n\n\n{{gastrointestinal-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Axelopran"}
